AcuCort (ACUC) Status update summary

Canadian agreement

• Exclusive licence and distribution agreement gives Kye rights to register, market, distribute and sell Zeqmelit in Canada.

• Regulatory submission planned for early 2027; launch expected in 2028, subject to Health Canada marketing authorisation.

• Terms include an upfront payment, regulatory and other milestone payments, product-supply revenue, and royalties on net sales.

Partner and strategy

• Kye launched seven innovative prescription products in Canada since 2024 and has an established presence in relevant segments, including paediatrics.

• Kye plans to use its paediatric sales organisation and extend Zeqmelit’s reach into allergy and respiratory diseases.

• Agreement advances international commercialization through established partners; Canada has more than 40 million people.

Commercial footprint

• Zeqmelit is marketed in Sweden, Denmark, Norway and Finland.

• Existing Glenmark agreement covers Germany, the Netherlands, the Czech Republic, Austria, Slovakia and Ukraine.